Merck KGaA licenses Glenmark diabetes drug
Germany's Merck KGaA has agreed to pay €25 million up front and up to €190 million in total to license Glenmark's DPP-4 inhibitor, GRC 8200, which is in Phase II trials. Glenmark retains marketing rights to India while Merck KGaA gains North America, Europe and Japan.
- see the press release on the pact
ALSO: As expected, Merck's Januvia has won FDA approval for type 2 diabetes. Analysts say that the drug, a new class of DPP-4 inhibitor, is likely to be a blockbuster along with Galvus, which is waiting on a decision from the FDA. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
